Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial

Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial

Abstract Background Metastatic colorectal cancer (mCRC) remains a significant clinical challenge, particularly for patients who have failed standard first- and second-line therapies. Despite advancements in targeted therapies, options for third-line treatments are limited, with current regimens such...

Full description

Saved in:
Bibliographic Details
Main Authors: Weibing Leng, Zhenpeng Wen, Han Wang, Peng Cao, Jiyan Liu, Deyun Luo, Meng Qiu
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Cancer
Subjects:
Metastatic colorectal cancer
S-1
Raltitrexed
Fruquintinib
RSF regimen
VEGFR inhibitor
Online Access:https://doi.org/10.1186/s12885-025-13654-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13654-7

Similar Items